GnRH antagonist in older IVF patients: Retrieval rates and clinical outcome

Journal of Reproductive Medicine for the Obstetrician and Gynecologist

Volumn 47, Issue 4, 2002, Pages 253-258

  Chang, Peter L ^a   Zeitoun, Khaled M ^a   Chan, Lai King ^a   Thornton II, Melvin H ^a   Sauer, Mark V ^a  

^a Beth Israel Center for Infertility   (United States)

Author keywords

Fertilization in vitro; Gonadotropin releasing hormone; Gonadotropin releasing hormone antagonist

Indexed keywords

FOLLITROPIN; GANIRELIX; GONADORELIN ANTAGONIST; HUMAN MENOPAUSAL GONADOTROPIN;

ADULT; ARTICLE; CONTROLLED STUDY; EMBRYO TRANSFER; ESTRUS CYCLE; FEMALE; FERTILIZATION IN VITRO; HUMAN; MAJOR CLINICAL STUDY; OOCYTE; OVARY HYPERSTIMULATION; OVULATION INDUCTION; PREGNANCY; PRIORITY JOURNAL; TREATMENT OUTCOME; UNITED STATES;

ADULT; AGE FACTORS; DRUG THERAPY, COMBINATION; FEMALE; FERTILITY AGENTS, FEMALE; FERTILIZATION IN VITRO; FOLLICLE STIMULATING HORMONE; GONADOTROPIN-RELEASING HORMONE; HORMONE ANTAGONISTS; HORMONES; HUMANS; MENOTROPINS; MENSTRUAL CYCLE; PREGNANCY; PREGNANCY OUTCOME; RETROSPECTIVE STUDIES;

EID: 0036234252     PISSN: 00247758     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (16)

1. An analysis of factors influencing the establishment of a clinical pregnancy in an ultrasound-based ambulatory in vitro fertilization program
2. In-vitro fertilization: Influence of women's age on pregnancy rates
3. Cumulative conception and livebirth rates after in-vitro fertilization
4. In vitro fertilization and embryo transfer in Israel: 1990 results from a national survey
5. The influence of advanced age on the outcome of assisted reproduction
6. Embryo quality and developmental potential is compromised by age
7. The control of endogenous secretion of LH by gonadotrophin-releasing hormone agonists during ovarian hyperstimulation for in-vitro fertilization and embryo transfer
8. A double-blind, randomized, dose-finding study to assess the efficacy of the gonadotrophin-releasing hormone antagonist Ganirelix (org 37462) to prevent premature luteinizing hormone surges in women undergoing ovarian stimulation with recombinant follicle stimulating hormone (Puregon)
9. Luteal phase and clinical outcome after human menopausal gonadotrophin/gonadotrophin releasing hormone antagonist treatment for ovarian stimulation in in-vitro fertilization/intracytoplasmic sperm injection cycles
10. Prospective, randomized, controlled study of in vitro fertilization-embryo transfer with a single dose of a luteinizing hormone-releasing hormone (LH-RH) antagonist (cetrorelix) or a depot formula of an LH-RH agonist (triptorelin)
11. Suppression of the endogenous luteinizing hormone surge by the gonadotrophin-releasing hormone antagonist cetrorelix during ovarian stimulation
12. The single or dual administration of the gonadotropin-releasing hormone antagonist cetrorelix in an in vitro fertilization-embryo transfer program
13. Scheduled administration of a gonadotrophin-releasing hormone antagonist (cetrorelix) on day 8 of in-vitro fertilization cycles: A pilot study
14. Ovarian stimulation for in-vitro fertilization/intracytoplasmic sperm injection with gonadotrophins and gonadotrophin-releasing hormone analogues: Agonists and antagonists
15. Addition of GnRH antagonist in cycles of poor responders undergoing IVF